Skip to main content
All Posts By

laurabbook@gmail.com

How Do I Handle This Cancer Part 4 Coping With Cancer

How Do I Handle This Cancer Part 4

*September 2020* by Tess Taft, msw, licsw ©all rights reserved This is the fourth part of a six-part series on how people cope with cancer. The first installment discussed GRIEF, DEPRESSION, and ANXIETY. The second installment included thoughts on ANGER.The third installment spoke to people who manage their feelings by WITHDRAWAL and RESIGNATION. DENIAL “I think…
laurabbook@gmail.com
October 16, 2020
Dovepress
Knockdown of IKKβ Inhibits Tumor Development in a Leptomeningeal Metastasis Mouse Model and Proliferation of Lung Cancer Cells ResearchTreatments

Knockdown of IKKβ Inhibits Tumor Development in a Leptomeningeal Metastasis Mouse Model and Proliferation of Lung Cancer Cells

*July 2020* Leptomeningeal metastasis (LM) is a devastating, late-stage complication of various solid tumors and is characterized by the diffuse dissemination of malignant tumor cells into the cerebrospinal fluid (CSF) and leptomeninges. Metastasis to this fluid-filled space can quickly spread to the entire central nervous system, leading to progressive neurological dysfunction…
laurabbook@gmail.com
September 18, 2020
Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series ResearchTreatments

Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series

*July 2020* While individualized oncologic treatments are becoming a common practice, it is necessary to evaluate brain metastases (BM) management in a homogeneous primitive population. In patients with a limited number of BM from NSCLC, SRT is an effective treatment associated with high local control rate, low neurological deterioration, and…
laurabbook@gmail.com
September 18, 2020
Targeted Oncology
Treatment Landscape Expands for EGFR-Mutated Non–Small Cell Lung Cancer ResearchTreatments

Treatment Landscape Expands for EGFR-Mutated Non–Small Cell Lung Cancer

*July 2020* In an interview with Targeted Oncology, Balazs Halmos, MD, MS, director of the Multidisciplinary Thoracic Oncology Program and director of the Section of Thoracic Medical Oncology for Montefiore Health Systems, and first director of Clinical Cancer Genetics and professor of clinical medicine at the Albert Einstein College of Medicine, discussed…
laurabbook@gmail.com
September 18, 2020
Targeted Oncology
FDA Accelerates Approval of Lurbinectedin in Metastatic SCLC ResearchTreatments

FDA Accelerates Approval of Lurbinectedin in Metastatic SCLC

*June 2020* The FDA had granted accelerated approval to the anti-cancer agent lurbinectedin (Zepzelca) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. The accelerated approval was granted in light of the positive overall response rate (ORR)…
laurabbook@gmail.com
September 18, 2020
Onc Live
Capmatinib Approved in Japan for METex14-Altered Advanced NSCLC ResearchTreatments

Capmatinib Approved in Japan for METex14-Altered Advanced NSCLC

*June 2020* Note: Capmatinib was approved by the FDA in May 2020 for MET exon 14 skipping mutation. The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved capmatinib (Tabrecta; formerly INC280) for patients with MET exon 14 skipping (METex14) mutation–positive advanced and/or recurrent unresectable non–small cell lung cancer (NSCLC), according to Novartis, the…
laurabbook@gmail.com
September 18, 2020
First-Line Osimertinib/Bevacizumab for Metastatic EGFR-Mutant Lung Cancer ResearchTreatments

First-Line Osimertinib/Bevacizumab for Metastatic EGFR-Mutant Lung Cancer

*July 2020* In the trial, 49 patients enrolled between August 2016 and May 2018 at Memorial Sloan Kettering Cancer Center received osimertinib at 80 mg daily and bevacizumab at 15 mg/kg once every 3 weeks, the maximum-tolerated dose identified in the phase I portion of the trial. The primary outcome…
laurabbook@gmail.com
September 18, 2020